Depo-Provera Lawsuit Settlement Amounts [2026 Projections]

Estimated settlement values in a Depo Provera meningioma lawsuit may range from approximately $150,000 to more than $1 million, depending on the severity of the claimant’s injuries and treatment.

Average settlements in other meningioma lawsuits have exceeded $800,000, although that figure does not establish an average payout for the current Depo-Provera litigation.

Some claims involving surgery, permanent neurological impairment, recurrent meningioma brain tumors, or extensive future medical care may exceed $1 million.

More than 5,830 lawsuits had been filed against Pfizer in the federal litigation as of 2026. The Depo-Provera MDL grew by nearly 4,000% in one year, demonstrating the substantial increase in claims involving alleged brain tumor injuries.

The projected Depo settlement tiers below illustrate how diagnosis, treatment severity, long-term impairment, and financial losses may affect an individual claim’s potential value.

Disclaimer: Please be advised that any projected or estimated settlement amounts mentioned on this page are general estimations and are not guaranteed. These figures are based on similar previous litigations, the nature of injuries sustained, and estimated costs of damages. They are meant to provide a general idea of what settlement ranges could look like and should not be taken as definitive expectations for your case.

Every legal case is unique, with its own specific circumstances that can significantly affect the outcome. This information is not legal advice and does not address the specifics of your situation. To obtain a more accurate understanding of the potential value of your case, it is best to consult directly with a qualified attorney who can provide personalized guidance.

Tier One Estimates: $650,000 to $1.5 Million or More — Severe Cases

The highest projected settlement range may apply to a Depo Provera claim involving extensive treatment, permanent neurological damage, or substantial financial losses.

These cases may allege that long term Depo Provera use caused a meningioma and that the injectable contraceptive manufacturer failed to provide adequate warnings about the risk.

Factors that may place a claim within this tier include:

• One or more brain or spinal surgeries
• Radiation therapy or other intensive treatment
• Permanent cognitive, motor, sensory, or speech impairment
• Seizures, vision loss, hearing loss, paralysis, or severe memory problems
• A recurrent, residual, inoperable, or higher-grade meningioma
• Permanent disability or substantial loss of earning capacity
• Significant future medical care, rehabilitation, or personal assistance

A Depo Provera attorney will review the claimant’s medical history, injection records, tumor location, treatment, prognosis, and documented losses when estimating potential value.

Evidence supporting the allegation that the birth control shot led to permanent impairment or lifelong care needs may substantially increase the projected settlement amount.

These figures are illustrative estimates rather than official tiers established by the Depo-Provera settlement agreement, and no individual recovery is guaranteed.

Tier Two: $300,000 to $650,000 — Moderate Cases

This projected range may apply to a Depo shot lawsuit involving substantial treatment, continuing symptoms, or measurable financial losses without the most severe permanent impairments.

These claims may involve women who were prescribed Depo Provera as a birth control injection and were later diagnosed with a meningioma.

Factors that may place a claim within this tier include:

• Surgical removal of an intracranial or spinal meningioma
• Radiation therapy or another form of active treatment
• An inoperable or residual tumor requiring continued monitoring
• Persistent headaches, balance problems, memory difficulties, vision changes, or seizures
• Partial neurological impairment or work restrictions
• Temporary disability or reduced earning capacity
• Ongoing specialist care, medication, imaging, or rehabilitation

Women developing meningioma brain tumors may fall within this range even if they did not undergo surgery, particularly when the tumor is inoperable or causes serious ongoing symptoms.

Depo-Provera lawsuit lawyers will evaluate the claimant’s treatment, prognosis, income losses, medical expenses, and effect on daily life when estimating potential compensation.

This range is an illustrative projection and does not represent an official payment category under the Depo-Provera settlement agreement.

Tier Three: $150,000 to $300,000 — Lower-Severity Cases

This projected range may apply to a Depo shot claim involving a confirmed meningioma that has not required surgery, radiation, or other intensive treatment.

These cases may involve women who used injectable birth control and were later diagnosed with a small, slow-growing, or asymptomatic tumor.

Factors that may place a claim within this tier include:

• A meningioma managed through observation and regular imaging
• No surgical removal or radiation treatment
• Mild or intermittent headaches, vision changes, or other symptoms
• Limited missed work or documented income loss
• No permanent neurological impairment
• Medical expenses related primarily to diagnosis, specialist visits, and continued monitoring
• A stable tumor with no evidence of recurrence or rapid growth

A claimant may still pursue compensation even when taking Depo Provera did not result in extensive treatment or permanent disability.

Attorneys will review the injection history, diagnosis, medical expenses, symptoms, and effect on daily life when estimating the potential value of the claim.

This range is an illustrative projection and does not represent an official settlement category or guaranteed payment.

Settlement amounts in a Depo Provera shot lawsuit may depend on the severity of the claimant’s meningioma, the treatment required, and the long-term effect on daily life and employment.

Although the Depo shot MDL is coordinated in federal court, each plaintiff retains an individual claim, so compensation may vary substantially from one case to another.

Factors that may affect settlement value include:

• The location, size, grade, and growth of the brain or spinal meningioma
• Whether the claimant required surgery, radiation, rehabilitation, or continued monitoring
• Permanent neurological symptoms, disability, or cognitive impairment
• Past and future medical expenses
• Lost wages and reduced earning capacity
• The number and duration of Depo-Provera injections
• The strength of the records connecting product use, diagnosis, and resulting damages
• The claimant’s age, prognosis, and expected future care needs

The strength of the scientific evidence concerning the risk of brain tumors may also affect negotiations and unresolved claims.

Pfizer’s alleged failure to warn patients and physicians about the risks of the medication is a central issue in this litigation involving dangerous drugs.

The confidential settlement criteria may consider additional factors that have not been disclosed publicly, so the projected ranges on this page are not official payment amounts or guarantees.

Depo-Provera lawsuits allege that repeated use of injectable medroxyprogesterone acetate increased the risk of meningioma and that Pfizer failed to provide an adequate warning.

The medication is a synthetic progestin that acts similarly to the hormone progesterone and received FDA approval for use as an injectable contraceptive.

FDA approval does not prevent patients from bringing claims based on allegations that a serious risk was not adequately disclosed.

Meningiomas form in the membranes surrounding the brain and spinal cord and account for approximately 30% to 40% of primary central nervous system tumors.

Most are noncancerous, but approximately 10% to 15% are classified as atypical or malignant and may carry greater risks of recurrence, neurological damage, and additional treatment.

Even a noncancerous meningioma can cause serious complications because of its size or location.

The Depo Provera label update became an important development in December 2025, when the FDA-approved prescribing information added a specific meningioma warning.

The revised label states that cases have been reported after repeated medroxyprogesterone acetate administration, primarily with long-term use, and advises doctors to discontinue Depo-Provera when a meningioma is diagnosed.

The first bellwether trial had been scheduled for December 2026 before plaintiffs’ leadership and certain Pfizer defendants reached a global agreement in June 2026.

That agreement gives eligible federal plaintiffs an opportunity to resolve their claims, but its requirements and payment terms remain confidential, and it will not resolve every pending lawsuit.

The Depo-Provera MDL continues through general-causation proceedings and other coordinated pretrial work for unresolved cases, and the court’s current public calendar indicates that earlier trial scheduling may change.

Is There a Depo Provera Class Action Lawsuit?

No, there is not a class action lawsuit for Depo-Provera patients who have developed brain tumors.

Lawsuits surrounding prolonged Depo Provera use and the risk of developing brain tumors are being consolidated into multidistrict litigation (MDL).

MDL differs from a class action in that each plaintiff in an MDL retains their own individual lawsuit, allowing for personalized compensation based on their unique circumstances and damages.

In a class action, all plaintiffs are treated as part of a single entity, and any settlement or verdict is distributed equally among them.

MDL is often chosen for cases like these because it consolidates pretrial processes, such as discovery, while still preserving the individual nature of each claim.

The Depo Provera multidistrict litigation helps streamline the legal process, making it more efficient to handle a large number of similar lawsuits, while ensuring that each plaintiff’s specific circumstances are considered.

A groundbreaking study published in The British Medical Journal (BMJ) in 2024 revealed a concerning link between long-term use of the contraceptive injection Depo-Provera and the development of intracranial meningiomas, a type of brain tumor.

The study, conducted by researchers in France, analyzed data from over 18,000 women who underwent surgery to remove meningiomas, comparing their cases with a control group.

Meningiomas are typically benign tumors that grow in the protective membranes surrounding the brain and spinal cord, but they can lead to severe complications depending on their size and location.

The study’s findings raised alarm because it demonstrated a statistically significant increase in the risk of developing these tumors in women who had used Depo-Provera for more than 12 months.

The hormone in Depo-Provera, medroxyprogesterone acetate, is a synthetic form of the hormone progestin, which plays a key role in reproductive health.

However, prolonged exposure to this hormone has been found to influence the growth of meningiomas, particularly in individuals exposed to high levels of progestogens over time.

The study has led to renewed scrutiny of the drug and its safety profile, prompting calls for updated warning labels and further investigation into the health risks associated with Depo-Provera.

Findings from the BMJ study include:

• 5.6-fold increased risk: Women who used Depo-Provera for 12 months or more were found to have a 5.6-fold higher risk of developing intracranial meningiomas compared to non-users.
• Hormonal influence: The synthetic hormone medroxyprogesterone acetate, used in Depo-Provera, was identified as a key factor influencing tumor growth, especially with prolonged exposure.
• Tumor size and severity: Women who developed meningiomas after using Depo-Provera were more likely to require surgical intervention due to the size and location of their tumors, leading to significant medical costs and long-term health impacts.
• No similar risk in other contraceptives: The study found that other hormonal contraceptives, such as intrauterine devices (IUDs) containing levonorgestrel, did not show the same increased risk, suggesting the link may be specific to progestogens like medroxyprogesterone acetate.
• Call for updated warnings: The study’s findings have prompted discussions about the need for updated warning labels and further research into the long-term health risks of Depo-Provera.

This study has been pivotal in the growing body of evidence that suggests women using Depo-Provera for extended periods may face significant health risks, particularly when it comes to brain tumor development.

Symptoms of Intracranial Meningiomas

Intracranial meningiomas, which develop in the protective membranes surrounding the brain and spinal cord, can manifest in a variety of ways depending on their size, location, and growth rate.

While these tumors are typically benign, their presence in the brain can cause a range of neurological symptoms as they press on vital structures.

Early stages may not produce noticeable symptoms, but as the tumor grows, it can begin to interfere with brain function, leading to more severe complications.

The progression of symptoms often starts subtly, making early detection difficult, but as pressure on surrounding tissues increases, more pronounced and debilitating symptoms emerge.

Common symptoms of intracranial meningiomas include:

• Persistent, severe headaches: Often the result of increased pressure within the skull, especially as the tumor grows.
• Vision problems: Blurred or double vision may occur if the tumor affects areas of the brain related to sight.
• Seizures: Tumor growth can trigger seizures, even in individuals with no prior history of epilepsy.
• Weakness or numbness: If the tumor presses on motor areas of the brain, it can lead to muscle weakness or numbness in the limbs.
• Cognitive or personality changes: Memory loss, confusion, or noticeable changes in behavior can result from the tumor’s impact on cognitive functions.
• Speech difficulties: Tumors affecting speech centers may cause slurred speech or difficulty finding words.
• Hearing loss: Tumors near auditory nerves may lead to partial or complete hearing loss.

As these symptoms progress, timely diagnosis and treatment become essential to managing the condition and preventing further neurological damage.

Complications of Intracranial Meningiomas

Depo-Provera related brain tumors, such as intracranial meningiomas, can lead to a variety of serious complications due to the tumor’s location and its impact on critical brain functions.

As these tumors grow, they can place pressure on surrounding brain tissue, nerves, and blood vessels, causing a range of neurological and physical issues.

Even though meningiomas are generally benign, their size and position can lead to significant and sometimes irreversible complications.

The severity of these complications often depends on how early the tumor is detected and whether it can be fully removed or treated through medical intervention.

Potential complications of these brain tumors include:

• Permanent neurological damage: Tumors pressing on critical areas of the brain can lead to lasting cognitive, motor, or sensory impairments.
• Seizures: Recurring seizures may develop, sometimes persisting even after the tumor is treated or removed.
• Vision loss: If the tumor affects the optic nerves, it can lead to partial or complete vision loss, which may be permanent.
• Paralysis or muscle weakness: Depending on the tumor’s location, it can cause weakness, numbness, or even paralysis in parts of the body.
• Cognitive decline: Some patients may experience significant memory loss, confusion, or other cognitive impairments that can affect daily living and quality of life.
• Chronic headaches: Persistent headaches may continue, even after treatment, due to long-term pressure on the brain.
• Difficulty speaking or understanding language: Tumors near language centers can lead to speech difficulties or impair the ability to understand communication.
• Blood clots: Depo-Provera use can increase the risk of developing blood clots, such as deep vein thrombosis (DVT), which may result in life-threatening conditions like pulmonary embolism if left untreated.

You may qualify for a Depo-Provera lawsuit if you received at least two injections and were later diagnosed with an intracranial or spinal meningioma.

Attorneys will review the specific product used, dates and duration of injections, diagnosis, treatment, and available medical records.

Claims may involve Depo-Provera CI, Depo-SubQ Provera 104, or certain authorized generic products containing medroxyprogesterone acetate.

A claimant may still qualify when the tumor is noncancerous, particularly if it required surgery, radiation, continued monitoring, or caused neurological symptoms.

Eligibility also depends on the applicable statute of limitations and any requirements established under the federal settlement program.

Meeting preliminary criteria does not guarantee acceptance into the settlement process or a particular amount of compensation.

Gathering Evidence for a Depo-Provera Brain Tumor Lawsuit

Strong evidence is crucial to pursuing a Depo-Provera Brain Tumor Lawsuit.

Demonstrating a clear link between the long-term use of Depo-Provera and the development of a brain tumor, such as an intracranial meningioma, is key to proving liability and securing compensation.

Gathering comprehensive documentation of your medical condition, prescription history, and the impact on your life will help strengthen your case.

Potential evidence in a Depo-Provera Lawsuit may include:

• Injection and prescription records: Documentation showing when Depo-Provera was prescribed, administered, and how many injections the claimant received.
• Insurance and billing records: Claims, invoices, and payment records that help confirm Depo-Provera use when older medical records are incomplete.
• Diagnostic records: MRI scans, CT scans, radiology reports, and physician notes confirming an intracranial or spinal meningioma.
• Pathology and surgical records: Biopsy results, operative reports, tumor-grade information, and records from surgical removal or other procedures.
• Treatment records: Documentation of radiation therapy, medication, rehabilitation, neurological care, follow-up imaging, and ongoing monitoring.
• Medical history: Records identifying symptoms, prior conditions, other medications, and potential risk factors relevant to causation.
• Employment and financial records: Pay statements, tax records, disability documentation, and employer correspondence showing lost wages or reduced earning capacity.
• Evidence of daily limitations: Personal statements, caregiver accounts, and medical documentation describing seizures, headaches, vision problems, cognitive impairment, mobility restrictions, or other effects on quality of life.

Damages in Depo Provera Lawsuits

In legal terms, damages refer to the financial compensation a plaintiff may receive to account for the physical, emotional, and financial losses they have suffered as a result of harm caused by another party’s actions.

Damages are designed to compensate individuals for the significant impact the medication may have had on their health and quality of life.

A well-documented case can help you recover compensation for both direct costs, such as medical expenses, and less tangible losses, like pain and suffering.

Potential damages in a Depo-Provera Lawsuit may include:

• Medical expenses: Compensation for past and future medical bills, including surgeries, hospital stays, treatments, and ongoing care related to the brain tumor.
• Lost wages: Reimbursement for income lost due to time away from work during treatment or recovery, as well as reduced earning capacity if you are unable to return to your job.
• Pain and suffering: Damages awarded for the physical pain and emotional distress caused by the brain tumor, treatment, and resulting health complications.
• Loss of quality of life: Compensation for the diminished ability to enjoy life’s activities, hobbies, or relationships due to long-term or permanent impairments caused by the tumor.
• Disability or permanent impairment: If the brain tumor leads to a permanent disability or significant physical impairment, additional compensation may be pursued for the long-term impact on your life.
• Future medical care: Financial compensation for anticipated medical needs, such as ongoing therapies, medications, or future surgeries.

TorHoerman Law represents individuals who received Depo-Provera injections and were later diagnosed with an intracranial or spinal meningioma.

Our attorneys review injection records, imaging, surgical reports, treatment history, lost income, and other evidence needed to evaluate a potential claim.

Women across the country are filing lawsuits alleging that Pfizer and related companies failed to warn patients and prescribing clinicians about the meningioma risk associated with repeated Depo-Provera use.

Our legal team can explain how the federal MDL, current settlement process, filing deadlines, and unresolved litigation may affect your options.

If you or a loved one developed a meningioma after using Depo-Provera, contact TorHoerman Law for a free, confidential case evaluation.

You pay no upfront legal fees, and our firm receives a fee only if compensation is recovered for your claim.